ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Diosmetin, an active ingredient of Schizonepeta tenuifolia, alleviates acne by regulating inflammation and oxidative stress.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diosmetin Alleviates MRSA-Induced Pneumonia in Mice by Inhibiting NLRP3 Inflammasome Activation and NF-κB Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To elucidate the mechanism of Schizonepeta tenuifolia-Diosmetin in acne treatment using an integrated approach combining network pharmacology, molecular dynamics simulation, and experimental validation. Acne-related expression datasets were acquired from GEO, with differentially expressed genes (DEGs) identified using R. Regulatory patterns were visualized via volcano plots and heatmaps. Enrichment analyses (GO and KEGG) revealed significant biological processes and pathways. Candidate targets were screened using LASSO regression and PPI network analysis, followed by drug discovery via the Coremine Medical database. Molecular docking and dynamics simulations assessed compound-target binding stability. To evaluate the in vitro effects of diosmetin, this study employed the HaCaT keratinocyte model. Cell viability and inflammatory cytokine expression levels following drug treatment were assessed using the CCK-8 assay and ELISA, respectively. Western blot analysis was used to investigate the effects of diosmetin proteins such as NF-κB, Nrf2, and KLK7. Immunofluorescence was used to detect ROS levels and mitochondrial morphological changes. GO and KEGG enrichment analyses revealed that DEGs were significantly enriched in pathways related to mitochondrial function and ROS. PPI network analysis further identified potential hub genes. Molecular docking and dynamics simulations suggested that diosmetin, an active component of S. tenuifolia, binds strongly to KLK7. Diosmetin (Dios) restored KLK7 levels, reduced ROS accumulation, and improved mitochondrial dysfunction induced by acne. Furthermore, the study found that diosmetin significantly reduced ear swelling and alleviated inflammation, providing preliminary preclinical evidence for its treatment of acne. The pathogenesis of acne is related to inflammation and oxidative stress. The anti-acne effect of S. tenuifolia is mainly mediated by diosmetin, which can alleviate oxidative stress and reduce inflammatory responses. This study provides supportive evidence for the potential application of diosmetin in acne treatment.
Indexed as
Identifiers
41706149What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.